Literature DB >> 25520883

Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer.

Laura von der Emde1, Diane Goltz2, Stefan Latz1, Stefan C Müller1, Glen Kristiansen2, Jörg Ellinger1, Isabella Syring1.   

Abstract

Prostaglandins, especially prostaglandin E2 (PGE2), and COX-2 play an important role in carcinogenesis of many tumors including bladder cancer (BCA). The PGE2 receptors EP1-4 regulate tumor cell growth, invasion and migration in different tumor entities but EP expression in BCA remains to be determined. In the present study we examined the expression of EP1-4 in non-muscle invasive bladder cancer (NMIBC), muscle invasive bladder cancer (MIBC) and normal urothelial tissue (NU) using immunohistochemistry. Nuclear and cytoplasmic EP1-4 expression was correlated with clinicopathological parameters and survival of BCA patients. EP1, EP2 and EP3 were significantly less expressed in the cytoplasm und nucleus of NMIBC and MIBC than in NU; EP4 cytoplasmic staining in MIBC was significantly higher compared to NU. The cytoplasmic staining was significantly more abundant in MIBC than in NMIBC in all investigated receptors except EP2. The level of EP staining in NMIBC was correlated with staging and grading, especially cytoplasmic EP1. Nuclear staining of EP1 was an independent predictor of BCA recurrence-free survival in NMIBC patients. EP receptors are dysregulated in BCA. The increase of EP1 may be used as prognostic parameter in NMIBC patients and its dysregulation could be targeted by specific EP1 inhibitors.

Entities:  

Keywords:  Bladder cancer; EP1; EP2; EP3; EP4; immunohistochemistry; prostaglandin receptors

Year:  2014        PMID: 25520883      PMCID: PMC4266727     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  38 in total

1.  Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway.

Authors:  Juanjuan Wu; Yushan Zhang; Nicole Frilot; Jae I Kim; Wan-Ju Kim; Yehia Daaka
Journal:  J Biol Chem       Date:  2011-08-10       Impact factor: 5.157

2.  Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model.

Authors:  Xiping Xin; Mousumi Majumder; Gannareddy V Girish; Vik Mohindra; Takayuki Maruyama; Peeyush K Lala
Journal:  Lab Invest       Date:  2012-05-28       Impact factor: 5.662

3.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

4.  Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development.

Authors:  T Kawamori; N Uchiya; S Nakatsugi; K Watanabe; S Ohuchida; H Yamamoto; T Maruyama; K Kondo; T Sugimura; K Wakabayashi
Journal:  Carcinogenesis       Date:  2001-12       Impact factor: 4.944

5.  Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis.

Authors:  K Watanabe; T Kawamori; S Nakatsugi; T Ohta; S Ohuchida; H Yamamoto; T Maruyama; K Kondo; F Ushikubi; S Narumiya; T Sugimura; K Wakabayashi
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

6.  The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia.

Authors:  Sung-Hee Chang; Youxi Ai; Richard M Breyer; Timothy F Lane; Timothy Hla
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

7.  Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities.

Authors:  Xinrong Ma; Namita Kundu; Olga B Ioffe; Olga Goloubeva; Raymond Konger; Claudia Baquet; Phyllis Gimotty; Jocelyn Reader; Amy M Fulton
Journal:  Mol Cancer Res       Date:  2010-09-21       Impact factor: 5.852

Review 8.  Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer?

Authors:  Mark A Hull; Stanley C W Ko; Gillian Hawcroft
Journal:  Mol Cancer Ther       Date:  2004-08       Impact factor: 6.261

9.  Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence.

Authors:  Simon D Chell; Ian R Witherden; Richard R Dobson; Morganaden Moorghen; Andrew A Herman; David Qualtrough; Ann C Williams; Christos Paraskeva
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

10.  Prostanoid receptor EP1 expression in breast cancer.

Authors:  Mangesh A Thorat; Akira Morimiya; Sanjana Mehrotra; Raymond Konger; Sunil S Badve
Journal:  Mod Pathol       Date:  2007-09-28       Impact factor: 7.842

View more
  9 in total

1.  Decursinol angelate inhibits PGE2-induced survival of the human leukemia HL-60 cell line via regulation of the EP2 receptor and NFκB pathway.

Authors:  Adeeb Shehzad; Salman Ul Islam; Eun-Mi Ahn; You Mie Lee; Young Sup Lee
Journal:  Cancer Biol Ther       Date:  2016-07-14       Impact factor: 4.742

2.  Activation of PGE2/EP2 and PGE2/EP4 signaling pathways positively regulate the level of PD-1 in infiltrating CD8+ T cells in patients with lung cancer.

Authors:  Jinhong Wang; Li Zhang; Dong Kang; Deguang Yang; Ying Tang
Journal:  Oncol Lett       Date:  2017-10-26       Impact factor: 2.967

3.  Chronic inflammation in urothelial bladder cancer.

Authors:  Gabriella Nesi; Stefania Nobili; Tommaso Cai; Saverio Caini; Raffaella Santi
Journal:  Virchows Arch       Date:  2015-08-12       Impact factor: 4.064

4.  Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression.

Authors:  Eiji Kashiwagi; Satoshi Inoue; Taichi Mizushima; Jinbo Chen; Hiroki Ide; Takashi Kawahara; Leonardo O Reis; Alexander S Baras; George J Netto; Hiroshi Miyamoto
Journal:  Br J Cancer       Date:  2017-11-09       Impact factor: 7.640

5.  Targeting intracellular B2 receptors using novel cell-penetrating antagonists to arrest growth and induce apoptosis in human triple-negative breast cancer.

Authors:  Céléna Dubuc; Martin Savard; Veronica Bovenzi; Andrée Lessard; Audrey Fortier; Jérôme Côté; Witold Neugebauer; Flavio Rizzolio; Sameh Geha; Antonio Giordano; Sylvain Chemtob; Fernand Gobeil
Journal:  Oncotarget       Date:  2018-01-05

6.  EP4 and Class III β-Tubulin Expression in Uterine Smooth Muscle Tumors: Implications for Prognosis and Treatment.

Authors:  Jocelyn Reader; Amy K Harper; Teklu Legesse; Paul N Staats; Olga Goloubeva; Gautam G Rao; Amy Fulton; Dana M Roque
Journal:  Cancers (Basel)       Date:  2019-10-18       Impact factor: 6.639

Review 7.  Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other?

Authors:  Irati Beltrán Hernández; Jannes Z Kromhout; Erik Teske; Wim E Hennink; Sebastiaan A van Nimwegen; Sabrina Oliveira
Journal:  Theranostics       Date:  2021-02-06       Impact factor: 11.556

8.  Immunological significance of alternative splicing prognostic signatures for bladder cancer.

Authors:  Xinyun Li; Lin Yang; Wei Huang; Bo Jia; Yu Lai
Journal:  Heliyon       Date:  2022-02-19

9.  Prostaglandin E2 promotes human CD34+ cells homing through EP2 and EP4 in vitro.

Authors:  Yaqun Wang; Shuping Lai; Jing Tang; Chun Feng; Fangjie Liu; Chang Su; Waiyi Zou; Huizhen Chen; Duorong Xu
Journal:  Mol Med Rep       Date:  2017-05-30       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.